Lars Breivik

1.1k total citations
25 papers, 379 citations indexed

About

Lars Breivik is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Lars Breivik has authored 25 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Genetics and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Lars Breivik's work include Adrenal Hormones and Disorders (17 papers), Diabetes and associated disorders (11 papers) and Cardiac Ischemia and Reperfusion (6 papers). Lars Breivik is often cited by papers focused on Adrenal Hormones and Disorders (17 papers), Diabetes and associated disorders (11 papers) and Cardiac Ischemia and Reperfusion (6 papers). Lars Breivik collaborates with scholars based in Norway, Sweden and Russia. Lars Breivik's co-authors include Eystein S. Husebye, Anne K. Jonassen, Eva‐Katrine Aarnes, Jelena Mrdalj, Anette S. B. Wolff, Bergithe E Oftedal, Eirik Bratland, Elizaveta Orlova, Marianne Aardal Grytaas and Olle Kämpe and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Lars Breivik

23 papers receiving 373 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Breivik Norway 11 158 145 86 81 80 25 379
Erik Lindgren Sweden 11 54 0.3× 17 0.1× 35 0.4× 22 0.3× 6 0.1× 18 455
Shi-Han Chen United States 13 6 0.0× 66 0.5× 54 0.6× 141 1.7× 7 0.1× 19 458
Henry K. Su United States 12 148 0.9× 29 0.2× 16 0.2× 22 0.3× 14 0.2× 21 351
Ibrahim Abdullah United States 8 18 0.1× 26 0.2× 19 0.2× 32 0.4× 4 0.1× 20 416
Rohan Kumar United Kingdom 11 44 0.3× 15 0.1× 4 0.0× 19 0.2× 30 0.4× 34 297
Masaki Komatsu Japan 12 74 0.5× 9 0.1× 7 0.1× 73 0.9× 5 0.1× 24 373
Divya Salhan United States 11 23 0.1× 63 0.4× 32 0.4× 16 0.2× 1 0.0× 25 352
P. Di Emidio France 9 14 0.1× 43 0.3× 10 0.1× 11 0.1× 6 0.1× 16 287
Zheng Gong China 11 6 0.0× 31 0.2× 15 0.2× 9 0.1× 80 1.0× 41 395
Xiongjie Shen China 10 144 0.9× 104 0.7× 12 0.1× 44 0.5× 1 0.0× 13 488

Countries citing papers authored by Lars Breivik

Since Specialization
Citations

This map shows the geographic impact of Lars Breivik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Breivik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Breivik more than expected).

Fields of papers citing papers by Lars Breivik

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Breivik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Breivik. The network helps show where Lars Breivik may publish in the future.

Co-authorship network of co-authors of Lars Breivik

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Breivik. A scholar is included among the top collaborators of Lars Breivik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Breivik. Lars Breivik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sulen, André, Lars Breivik, Silke Appel, et al.. (2025). Anti-perilipin-1 autoantibodies in autoimmune Addison’s disease and related endocrine disorders. Autoimmunity. 58(1). 2461703–2461703. 1 indexed citations
2.
Filippov, Igor, André Sulen, Lars Breivik, et al.. (2024). Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. iScience. 27(4). 109610–109610. 4 indexed citations
3.
Aranda‐Guillén, Maribel, Ellen C. Røyrvik, Ileana Ruxandra Botusan, et al.. (2023). A polygenic risk score to help discriminate primary adrenal insufficiency of different etiologies. Journal of Internal Medicine. 294(1). 96–109. 7 indexed citations
4.
Stokland, Ann‐Elin Meling, Marie Austdal, Bjørn Gunnar Nedrebø, et al.. (2023). Outcomes of Patients With Graves Disease 25 Years After Initiating Antithyroid Drug Therapy. The Journal of Clinical Endocrinology & Metabolism. 109(3). 827–836. 11 indexed citations
5.
Oftedal, Bergithe E, Øyvind Bruserud, Yael Goldfarb, et al.. (2023). A partial form of AIRE deficiency underlies a mild form of autoimmune polyendocrine syndrome type 1. Journal of Clinical Investigation. 133(21). 5 indexed citations
6.
Wolff, Anette S. B., Lena Hansen, Bergithe E Oftedal, et al.. (2023). Vaccination prevents severe COVID-19 outcome in patients with neutralizing type 1 interferon autoantibodies. iScience. 26(7). 107084–107084. 4 indexed citations
7.
Wolff, Anette S. B., Lars Breivik, Karl Ove Hufthammer, et al.. (2021). The natural history of 21-hydroxylase autoantibodies in autoimmune Addison’s disease. European Journal of Endocrinology. 184(4). 607–615. 20 indexed citations
8.
Hellesen, Alexander, Lars Breivik, Ellen C. Røyrvik, et al.. (2021). 21-Hydroxylase-Specific CD8+ T Cells in Autoimmune Addison’s Disease Are Restricted by HLA-A2 and HLA-C7 Molecules. Frontiers in Immunology. 12. 742848–742848. 4 indexed citations
9.
Wolff, Anette S. B., Magnus Dehli Vigeland, Lars Breivik, et al.. (2019). Identification and characterization of rare toll-like receptor 3 variants in patients with autoimmune Addison's disease. SHILAP Revista de lepidopterología. 1. 100005–100005. 4 indexed citations
10.
Orlova, Elizaveta, Leila Sozaeva, Maria Kareva, et al.. (2017). Expanding the Phenotypic and Genotypic Landscape of Autoimmune Polyendocrine Syndrome Type 1. The Journal of Clinical Endocrinology & Metabolism. 102(9). 3546–3556. 80 indexed citations
11.
Breivik, Lars, et al.. (2017). Insulin and GSK3β-inhibition abrogates the infarct sparing-effect of ischemic postconditioning in ex vivo rat hearts. Scandinavian Cardiovascular Journal. 51(3). 159–166. 5 indexed citations
12.
13.
Hellesen, Alexander, et al.. (2015). Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro , Despite Elevated Serum Levels of Interferon-Inducible Chemokines. Journal of Interferon & Cytokine Research. 35(10). 759–770. 16 indexed citations
14.
Orlova, Elizaveta, et al.. (2015). The new immunological methods for diagnostics of type 1 autoimmune polyendocrine syndrome (the first experience in Russia). Problems of Endocrinology. 61(5). 9–13. 2 indexed citations
15.
16.
Breivik, Lars, et al.. (2014). Exploring the Human Plasma Proteome for Humoral Mediators of Remote Ischemic Preconditioning - A Word of Caution. PLoS ONE. 9(10). e109279–e109279. 16 indexed citations
17.
Breivik, Lars, Bergithe E Oftedal, Anette S. B. Wolff, et al.. (2014). A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1. Clinical Immunology. 153(1). 220–227. 16 indexed citations
18.
Hellesen, Alexander, et al.. (2014). The effect of types I and III interferons on adrenocortical cells and its possible implications for autoimmune Addison's disease. Clinical & Experimental Immunology. 176(3). 351–362. 10 indexed citations
19.
Breivik, Lars, et al.. (2013). Influence of Feeding and Intracoronary Dose on Insulin‐Mediated Relative Akt Phosphorylation in the Porcine Myocardium. Cardiovascular Therapeutics. 31(6). e125–32. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erik Lindgren Breakdown of academic impact, for papers by Shi-Han Chen Breakdown of academic impact, for papers by Henry K. Su Breakdown of academic impact, for papers by Ibrahim Abdullah Breakdown of academic impact, for papers by Rohan Kumar Breakdown of academic impact, for papers by Masaki Komatsu Breakdown of academic impact, for papers by Divya Salhan Breakdown of academic impact, for papers by P. Di Emidio Breakdown of academic impact, for papers by Zheng Gong Breakdown of academic impact, for papers by Xiongjie Shen
Rankless by CCL
2026